Ligand Pharmaceuticals (LGND) Liabilities from Discontinued Operations (2021 - 2025)
Ligand Pharmaceuticals (LGND) reported Liabilities from Discontinued Operations of 35692000.0 for Q2 2025, up 39.92% sequentially from 25509000.0 in Q1 2025.
Ligand Pharmaceuticals (LGND) Liabilities from Discontinued Operations (2021 - 2025) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 35692000.0 in Q2 2025.
- For the quarter ending Q2 2025, Liabilities from Discontinued Operations changed N/A year-over-year to 35692000.0; the trailing twelve-month figure through Jun 2025 stood at 35692000.0 (changed N/A YoY), and the FY2021 full-year result was 13566000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations climbed to 35692000.0 in Q2 2025, from 25509000.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 35692000.0 in Q2 2025 to a low of 13566000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 35.69 Mn |
| Jun 30, 2025 | 35.69 Mn |
| Mar 31, 2025 | 25.51 Mn |
| Mar 31, 2025 | 25.51 Mn |
| Dec 31, 2021 | 13.57 Mn |
| Dec 31, 2021 | 13.57 Mn |